7 completed. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 1 | Completed 1 |
Follow Chronic Cough: new trials by email Literature Review of Chronic Cough trials Research Report on Chronic Cough
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration HRS-2261 tablet、placebo - Chronic Cough | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 92 | 2022-03-28 | 2023-04-05 |
| Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI) - Refractory Chronic Cough | Phase 1 | Completed | Nocion Therapeutics | 24 | 2022-02-07 | 2023-03-30 |
| Cough Desensitization Therapy: Pilot 2 Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer, Saline - Cough | Phase 1 | Completed | University of Montana | 22 | 2021-05-01 | 2022-11-03 |
| Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants Rosuvastatin, Rosuvastatin + BAY1817080 - Drug Interactions | Phase 1 | Completed | Bayer | 14 | 2020-03-02 | 2021-03-11 |
| A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein BAY1817080 - Formulation A, BAY1817080 - Formulation B, [13C715N]-BAY 181708 stable isotope label (SIL) - Biological Availability | Phase 1 | Completed | Bayer | 30 | 2018-12-13 | 2019-08-19 |
| Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients BAY1817080, Matching Placebo - Cough | Phase 1 / Phase 2 | Completed | Bayer | 87 | 2017-12-07 | 2023-01-26 |
| The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects GSK2339345 (solution), GSK2339345 (nebulised), Placebo (0.9% sodium chloride solution) - Cough | Phase 1 | Completed | GlaxoSmithKline | 31 | 2011-10-17 | 2017-06-20 |
Cough (3) · Endometriosis (1) · Pain (1)
Pathological Conditions, Signs and Symptoms (7) · Respiration Disorders (7) · Respiratory Tract Diseases (7) · Signs and Symptoms (7) · Signs and Symptoms, Respiratory (7) · Cough (4) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Neurologic Manifestations (1) · Urogenital Diseases (1)
Sodium Chloride (2) · Lidocaine (1) · Rosuvastatin Calcium (1) · Solutions (1)
Bayer (3) · GlaxoSmithKline (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Nocion Therapeutics (1) · University of Montana (1)
United States (3) · United Kingdom (2) · China (1) · Netherlands (1)
Christopher Silber, MD (1) · Laurie Slovarp, PhD (1)
PMID 33986030, PMID 35624408, PMID 36469250, PMID 37118696, PMID 38044419, PMID 38198010
2017 (1), 2018 (1)